Please wait while the formulary information is being retrieved.
Drug overview for CYCLOSERINE (cycloserine):
Generic name: CYCLOSERINE (sye-klo-SER-een)
Drug class: Cycloserines
Therapeutic class: Anti-Infective Agents
Cycloserine, a structural analog of the amino acid d-alanine, is an antituberculosis antibiotic.
No enhanced Uses information available for this drug.
Generic name: CYCLOSERINE (sye-klo-SER-een)
Drug class: Cycloserines
Therapeutic class: Anti-Infective Agents
Cycloserine, a structural analog of the amino acid d-alanine, is an antituberculosis antibiotic.
No enhanced Uses information available for this drug.
DRUG IMAGES
CYCLOSERINE 250 MG CAPSULE
The following indications for CYCLOSERINE (cycloserine) have been approved by the FDA:
Indications:
Active tuberculosis
E. coli urinary tract infection
Enterobacter cloacae urinary tract infection
Pulmonary tuberculosis
Professional Synonyms:
Active TB
Acute tuberculosis
E. coli UTI
Pulmonary TB
Urinary tract infection due to Enterobacter cloacae
Urinary tract infection due to Escherichia coli
UTI due to Enterobacter cloacae
Indications:
Active tuberculosis
E. coli urinary tract infection
Enterobacter cloacae urinary tract infection
Pulmonary tuberculosis
Professional Synonyms:
Active TB
Acute tuberculosis
E. coli UTI
Pulmonary TB
Urinary tract infection due to Enterobacter cloacae
Urinary tract infection due to Escherichia coli
UTI due to Enterobacter cloacae
The following dosing information is available for CYCLOSERINE (cycloserine):
Dosage of cycloserine in patients with renal impairment must be adjusted according to the degree of dysfunction and blood cycloserine concentrations.
Cycloserine is administered orally.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CYCLOSERINE 250 MG CAPSULE | Maintenance | Adults take 1 capsule (250 mg) by oral route every 12 hours |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CYCLOSERINE 250 MG CAPSULE | Maintenance | Adults take 1 capsule (250 mg) by oral route every 12 hours |
The following drug interaction information is available for CYCLOSERINE (cycloserine):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Live BCG/Selected Antimycobacterials SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Bacillus Calmette-Guerin (BCG) is a live, attenuated strain of Mycobacterium bovis (M.bovis) used to induce a granulomatous response in the treatment of localized bladder cancer and as a vaccine to prevent tuberculosis.(1-2) Co-treatment with antibacterial agents active against M.bovis may lead to an attenuation of the immune response associated with BCG administration.(1-2) CLINICAL EFFECTS: The effectiveness of chemotherapy may be impaired, or the vaccine may be ineffective. Agents linked to this monograph may have activity against M.bovis: amikacin, capreomycin, ciprofloxacin, clofazimine, cycloserine, ethambutol, ethionamide, gatifloxacin, isoniazid, kanamycin, levofloxacin, moxifloxacin, ofloxacin, rifabutin, rifampin, rifapentine, and streptomycin. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Intravesical instillation of BCG should be postponed during treatment with antibacterials which may decrease effectiveness.(2) Administration of BCG vaccine to patients receiving antibiotic therapy should only be done under close medical supervision.(1) If a patient develops a systemic BCG infection due to intravesicular or vaccine administration, treatment with multiple antimycobacterial agents may be required. DISCUSSION: Because antibiotic therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of BCG vaccine states that administration of BCG vaccine to patients receiving antibiotic therapy should only be done under close medical supervision.(1) Pyrazinamide is not included in this interaction as BCG is not sensitive to pyrazinamide.(2) |
BCG (TICE STRAIN), BCG VACCINE (TICE STRAIN) |
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
There are 0 moderate interactions.
The following contraindication information is available for CYCLOSERINE (cycloserine):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 8 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Alcohol use disorder |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Depression |
| Generalized anxiety disorder |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Psychotic disorder |
| Seizure disorder |
There are 4 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Folate deficiency |
| Megaloblastic anemia |
| Sideroblastic anemia |
| Vitamin b12 deficiency |
There are 0 moderate contraindications.
The following adverse reaction information is available for CYCLOSERINE (cycloserine):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 20 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute cognitive impairment Altered mental status CNS toxicity Depression Dizziness Drowsy Dysphasia Irritability Mood changes Muscle fasciculation Nervousness Nightmares Suicidal ideation |
Allergic dermatitis Hypersensitivity drug reaction Peripheral neuropathy Pruritus of skin Seizure disorder Skin rash Urticaria |
| Rare/Very Rare |
|---|
| None. |
There are 3 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Headache disorder Symptoms of anxiety |
None. |
| Rare/Very Rare |
|---|
|
Anticholinergic toxicity |
The following precautions are available for CYCLOSERINE (cycloserine):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Reproduction studies in 2 generations of rats receiving cycloserine in dosages up to 100 mg/kg daily have not revealed evidence of teratogenicity. There are no adequate and controlled studies to date using cycloserine in pregnant women, and the drug should be used during pregnancy only when clearly needed. Because cycloserine crosses the placenta and data are limited regarding safety of the drug in pregnant women, the American Thoracic Society (ATS), US Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) state that the drug should be used for the treatment of tuberculosis during pregnancy only when there are no suitable alternatives.
Because of the potential for adverse effects from cycloserine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for CYCLOSERINE (cycloserine):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for CYCLOSERINE (cycloserine)'s list of indications:
| Active tuberculosis | |
| A15 | Respiratory tuberculosis |
| A15.0 | Tuberculosis of lung |
| A15.4 | Tuberculosis of intrathoracic lymph nodes |
| A15.5 | Tuberculosis of larynx, trachea and bronchus |
| A15.6 | Tuberculous pleurisy |
| A15.7 | Primary respiratory tuberculosis |
| A15.8 | Other respiratory tuberculosis |
| A15.9 | Respiratory tuberculosis unspecified |
| A17 | Tuberculosis of nervous system |
| A17.0 | Tuberculous meningitis |
| A17.1 | Meningeal tuberculoma |
| A17.8 | Other tuberculosis of nervous system |
| A17.81 | Tuberculoma of brain and spinal cord |
| A17.82 | Tuberculous meningoencephalitis |
| A17.83 | Tuberculous neuritis |
| A17.89 | Other tuberculosis of nervous system |
| A17.9 | Tuberculosis of nervous system, unspecified |
| A18 | Tuberculosis of other organs |
| A18.0 | Tuberculosis of bones and joints |
| A18.01 | Tuberculosis of spine |
| A18.02 | Tuberculous arthritis of other joints |
| A18.03 | Tuberculosis of other bones |
| A18.09 | Other musculoskeletal tuberculosis |
| A18.1 | Tuberculosis of genitourinary system |
| A18.10 | Tuberculosis of genitourinary system, unspecified |
| A18.11 | Tuberculosis of kidney and ureter |
| A18.12 | Tuberculosis of bladder |
| A18.13 | Tuberculosis of other urinary organs |
| A18.14 | Tuberculosis of prostate |
| A18.15 | Tuberculosis of other male genital organs |
| A18.16 | Tuberculosis of cervix |
| A18.17 | Tuberculous female pelvic inflammatory disease |
| A18.18 | Tuberculosis of other female genital organs |
| A18.2 | Tuberculous peripheral lymphadenopathy |
| A18.3 | Tuberculosis of intestines, peritoneum and mesenteric glands |
| A18.31 | Tuberculous peritonitis |
| A18.32 | Tuberculous enteritis |
| A18.39 | Retroperitoneal tuberculosis |
| A18.4 | Tuberculosis of skin and subcutaneous tissue |
| A18.5 | Tuberculosis of eye |
| A18.50 | Tuberculosis of eye, unspecified |
| A18.51 | Tuberculous episcleritis |
| A18.52 | Tuberculous keratitis |
| A18.53 | Tuberculous chorioretinitis |
| A18.54 | Tuberculous iridocyclitis |
| A18.59 | Other tuberculosis of eye |
| A18.6 | Tuberculosis of (inner) (middle) ear |
| A18.7 | Tuberculosis of adrenal glands |
| A18.8 | Tuberculosis of other specified organs |
| A18.81 | Tuberculosis of thyroid gland |
| A18.82 | Tuberculosis of other endocrine glands |
| A18.83 | Tuberculosis of digestive tract organs, not elsewhere classified |
| A18.84 | Tuberculosis of heart |
| A18.85 | Tuberculosis of spleen |
| A18.89 | Tuberculosis of other sites |
| A19 | Miliary tuberculosis |
| A19.0 | Acute miliary tuberculosis of a single specified site |
| A19.1 | Acute miliary tuberculosis of multiple sites |
| A19.2 | Acute miliary tuberculosis, unspecified |
| A19.8 | Other miliary tuberculosis |
| A19.9 | Miliary tuberculosis, unspecified |
| O98.0 | Tuberculosis complicating pregnancy, childbirth and the puerperium |
| O98.01 | Tuberculosis complicating pregnancy |
| O98.011 | Tuberculosis complicating pregnancy, first trimester |
| O98.012 | Tuberculosis complicating pregnancy, second trimester |
| O98.013 | Tuberculosis complicating pregnancy, third trimester |
| O98.019 | Tuberculosis complicating pregnancy, unspecified trimester |
| O98.02 | Tuberculosis complicating childbirth |
| O98.03 | Tuberculosis complicating the puerperium |
| P37.0 | Congenital tuberculosis |
| E. coli urinary tract infection | |
| B96.2 | Escherichia coli [e. coli ] as the cause of diseases classified elsewhere |
| B96.20 | Unspecified escherichia coli [e. coli] as the cause of diseases classified elsewhere |
| B96.29 | Other escherichia coli [e. coli] as the cause of diseases classified elsewhere |
| N30.0 | Acute cystitis |
| N30.00 | Acute cystitis without hematuria |
| N30.01 | Acute cystitis with hematuria |
| N30.9 | Cystitis, unspecified |
| N30.90 | Cystitis, unspecified without hematuria |
| N30.91 | Cystitis, unspecified with hematuria |
| N39.0 | Urinary tract infection, site not specified |
| O23.0 | Infections of kidney in pregnancy |
| O23.00 | Infections of kidney in pregnancy, unspecified trimester |
| O23.01 | Infections of kidney in pregnancy, first trimester |
| O23.02 | Infections of kidney in pregnancy, second trimester |
| O23.03 | Infections of kidney in pregnancy, third trimester |
| O23.1 | Infections of bladder in pregnancy |
| O23.10 | Infections of bladder in pregnancy, unspecified trimester |
| O23.11 | Infections of bladder in pregnancy, first trimester |
| O23.12 | Infections of bladder in pregnancy, second trimester |
| O23.13 | Infections of bladder in pregnancy, third trimester |
| O23.2 | Infections of urethra in pregnancy |
| O23.20 | Infections of urethra in pregnancy, unspecified trimester |
| O23.21 | Infections of urethra in pregnancy, first trimester |
| O23.22 | Infections of urethra in pregnancy, second trimester |
| O23.23 | Infections of urethra in pregnancy, third trimester |
| O23.3 | Infections of other parts of urinary tract in pregnancy |
| O23.30 | Infections of other parts of urinary tract in pregnancy, unspecified trimester |
| O23.31 | Infections of other parts of urinary tract in pregnancy, first trimester |
| O23.32 | Infections of other parts of urinary tract in pregnancy, second trimester |
| O23.33 | Infections of other parts of urinary tract in pregnancy, third trimester |
| O23.4 | Unspecified infection of urinary tract in pregnancy |
| O23.40 | Unspecified infection of urinary tract in pregnancy, unspecified trimester |
| O23.41 | Unspecified infection of urinary tract in pregnancy, first trimester |
| O23.42 | Unspecified infection of urinary tract in pregnancy, second trimester |
| O23.43 | Unspecified infection of urinary tract in pregnancy, third trimester |
| O23.9 | Unspecified genitourinary tract infection in pregnancy |
| O23.90 | Unspecified genitourinary tract infection in pregnancy, unspecified trimester |
| O23.91 | Unspecified genitourinary tract infection in pregnancy, first trimester |
| O23.92 | Unspecified genitourinary tract infection in pregnancy, second trimester |
| O23.93 | Unspecified genitourinary tract infection in pregnancy, third trimester |
| Enterobacter cloacae urinary tract infection | |
| B96.89 | Other specified bacterial agents as the cause of diseases classified elsewhere |
| N30.0 | Acute cystitis |
| N30.00 | Acute cystitis without hematuria |
| N30.01 | Acute cystitis with hematuria |
| N30.9 | Cystitis, unspecified |
| N30.90 | Cystitis, unspecified without hematuria |
| N30.91 | Cystitis, unspecified with hematuria |
| N39.0 | Urinary tract infection, site not specified |
| O23.0 | Infections of kidney in pregnancy |
| O23.00 | Infections of kidney in pregnancy, unspecified trimester |
| O23.01 | Infections of kidney in pregnancy, first trimester |
| O23.02 | Infections of kidney in pregnancy, second trimester |
| O23.03 | Infections of kidney in pregnancy, third trimester |
| O23.1 | Infections of bladder in pregnancy |
| O23.10 | Infections of bladder in pregnancy, unspecified trimester |
| O23.11 | Infections of bladder in pregnancy, first trimester |
| O23.12 | Infections of bladder in pregnancy, second trimester |
| O23.13 | Infections of bladder in pregnancy, third trimester |
| O23.2 | Infections of urethra in pregnancy |
| O23.20 | Infections of urethra in pregnancy, unspecified trimester |
| O23.21 | Infections of urethra in pregnancy, first trimester |
| O23.22 | Infections of urethra in pregnancy, second trimester |
| O23.23 | Infections of urethra in pregnancy, third trimester |
| O23.3 | Infections of other parts of urinary tract in pregnancy |
| O23.30 | Infections of other parts of urinary tract in pregnancy, unspecified trimester |
| O23.31 | Infections of other parts of urinary tract in pregnancy, first trimester |
| O23.32 | Infections of other parts of urinary tract in pregnancy, second trimester |
| O23.33 | Infections of other parts of urinary tract in pregnancy, third trimester |
| O23.4 | Unspecified infection of urinary tract in pregnancy |
| O23.40 | Unspecified infection of urinary tract in pregnancy, unspecified trimester |
| O23.41 | Unspecified infection of urinary tract in pregnancy, first trimester |
| O23.42 | Unspecified infection of urinary tract in pregnancy, second trimester |
| O23.43 | Unspecified infection of urinary tract in pregnancy, third trimester |
| O23.9 | Unspecified genitourinary tract infection in pregnancy |
| O23.90 | Unspecified genitourinary tract infection in pregnancy, unspecified trimester |
| O23.91 | Unspecified genitourinary tract infection in pregnancy, first trimester |
| O23.92 | Unspecified genitourinary tract infection in pregnancy, second trimester |
| O23.93 | Unspecified genitourinary tract infection in pregnancy, third trimester |
| Pulmonary tuberculosis | |
| A15 | Respiratory tuberculosis |
| A15.0 | Tuberculosis of lung |
| A15.7 | Primary respiratory tuberculosis |
| A15.8 | Other respiratory tuberculosis |
Formulary Reference Tool